Compare Enovix Corporation (ENVX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Novo Nordisk A/S — how do they compare? Enovix Corporation trades at $2.53 (market cap $549.72M), while Novo Nordisk A/S trades at $38.16 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 300.7× Enovix Corporation's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Novo Nordisk A/S for 116 Days on average.
| ENVX | NVO | |
|---|---|---|
Market Cap | $549.72M | $165.31B |
Volume | 6,635,687 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $13.19 | $63.98 |
52-Week Low | $2.50 | $35.29 |
Typical Hold Time | 11 Days | 116 Days |
Enterprise Value | $611.42M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% on the day, reflecting a bearish technical outlook with significant selling pressure indicated by moving averages and oscillators. Fundamentally, the company is in a high-growth, pre-profitability phase, with revenue growing to $36 million in 2026 but net losses widening to -$170 million. Recent news is dominated by a sudden CEO resignation in August 2026, though the company reaffirmed its strategy and operational guidance.
The investment case hinges on the company's advanced battery technology and expansion plans, particularly in the defense and drone sectors, against a backdrop of persistent cash burn and high execution risk. Analyst consensus remains bullish with a $10.75 price target, but the stock faces near-term volatility from leadership uncertainty and the challenging path to profitability.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
